{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025872","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.934808+00:00","generated_at":"2026-05-31T10:24:28.007479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024","bullets":["Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.","Net loss $2.7M ($6.43/share) for Q2 2024, compared to $4.0M ($38.74/share) in Q2 2023.","AJ201 Phase 1b/2a SBMA trial last patient visit complete; topline data expected in H2 2024.","Raised $4.4M gross proceeds from April 2024 warrant exercise; 1-for-75 reverse stock split effected.","Regained Nasdaq compliance in May 2024 after reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025872","json":"https://secwatch.observer/filing/0001437749-24-025872.json","markdown":"https://secwatch.observer/filing/0001437749-24-025872.md","text":"https://secwatch.observer/filing/0001437749-24-025872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/0001437749-24-025872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/atxi20240520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:24:28.007479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}